Get the Stockscreener App
0.2725
23.58%
-0.0841
After Hours:
.27
-0.0025
-0.92%
Transcode Therapeutics Inc stock is traded at $0.2725, with a volume of 5.56M.
It is down -23.58% in the last 24 hours and down -65.06% over the past month.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
See More
Previous Close:
$0.3566
Open:
$0.3507
24h Volume:
5.56M
Relative Volume:
0.80
Market Cap:
$285.46K
Revenue:
-
Net Income/Loss:
$-14.93M
P/E Ratio:
-0.00102
EPS:
-266.137
Net Cash Flow:
$-15.87M
1W Performance:
-31.64%
1M Performance:
-65.06%
6M Performance:
-98.62%
1Y Performance:
-98.35%
1-Day Range:
$0.2196
$0.3577
1-Week Range:
$0.2196
$0.4199
52-Week Range:
$0.2196
$66.33
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Name
Transcode Therapeutics Inc
Sector
Industry
Phone
857-301-6857
Address
6 LIBERTY SQUARE, BOSTON
Compare RNAZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
0.2725 | 285.46K | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Transcode Therapeutics Inc Stock (RNAZ) Latest News
All You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to Buy - MSN
HC Wainwright Cuts TransCode Therapeutics (NASDAQ:RNAZ) Price Target to $10.00 - Defense World
Research Analysts Offer Predictions for RNAZ Q1 Earnings - Defense World
Transcode Therapeutics stock hits 52-week low at $0.34 By Investing.com - Investing.com South Africa
Transcode Therapeutics stock hits 52-week low at $0.34 - Investing.com
An Open Letter to Shareholders of TransCode Therapeutics, Inc. Asking Stockholders to Vote FOR the Proposal to Authorize a Reverse Stock Split if Necessary - Yahoo Finance
Transcode Therapeutics, Inc. SEC 10-K Report - TradingView
TransCode Therapeutics Inc (NASDAQ: RNAZ) Stock: Bulls Should Watch This - stocksregister.com
Wynn Resorts Ltd (WYNN) Shares Plummet Below 1-Year High - News Heater
RNAZ stock touches 52-week low at $0.43 amid sharp annual decline By Investing.com - Investing.com South Africa
RNAZ stock touches 52-week low at $0.43 amid sharp annual decline - Investing.com
TransCode Therapeutics Inc’s Stock Price Plummeted Recently, But There Might Be Trouble Ahead - stocksregister.com
Best Penny Stocks Under $1 to Buy Now: April 2025 Watchlist - timothysykes.com
TransCode Therapeutics Delays Annual Report Filing - TipRanks
TransCode Therapeutics (RNAZ) Expected to Announce Earnings on Monday - Defense World
Emerging Tech QuartetPRSO, LXRX, PRTG, RNAZDrive - openPR.com
Pre-market Movers: PRTG, RNAZ, PTIX, LGMK... - RTTNews
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
TransCode Therapeutics stock slides after announces to raise $10M securities offering - MSN
(RNAZ) Investment Analysis - news.stocktradersdaily.com
Small Cap Stocks To Follow TodayMarch 23rd - MarketBeat
TransCode Therapeutics, Inc. Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial Withttx-Mc138 - MarketScreener
TransCode Therapeutics Starts Dosing for Experimental Cancer Treatment in Early Trial - Marketscreener.com
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
TransCode's $10M Capital Raise Powers Critical Cancer Drug Clinical Trials - Stock Titan
Biotech Alert: Searches spiking for these stocks today - TipRanks
TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering - PR Newswire
Transcode Therapeutics stock hits 52-week low at $0.64 By Investing.com - Investing.com Australia
TransCode Therapeutics Announces $10M Stock And Warrant Offering - Nasdaq
Sector Update: Health Care Stocks Rise Late Afternoon - TradingView
Transcode Therapeutics stock hits 52-week low at $0.64 - Investing.com India
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Transcode to sell 10.25M shares at 98c per share in registered direct offering - TipRanks
Why AZEK Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
TransCode Therapeutics Starts $10 Million Direct Offering of Stock, Warrants -March 24, 2025 at 03:42 am EDT - Marketscreener.com
$10M Capital Raise: TransCode Therapeutics Accelerates TTX-MC138 Clinical Trials - Stock Titan
TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - PR Newswire
Small Cap Stocks To ResearchMarch 21st - MarketBeat
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
(RNAZ) Long Term Investment Analysis - Stock Traders Daily
HC Wainwright Reaffirms “Buy” Rating for TransCode Therapeutics (NASDAQ:RNAZ) - Defense World
RNAZ stock touches 52-week low at $0.69 amid sharp annual decline - Investing.com Canada
SRC approves opening of TransCode’s fourth cohort in trial of TTX-MC138 - Yahoo Finance
Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Benzinga
TransCode Therapeutics Advances Phase I Trial Of RNA Cancer Therapy - Nasdaq
Transcode Therapeutics’ fourth cohort in Phase 1/2 cancer trial approved - TipRanks
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
TransCode Therapeutics Says Safety Review Committee Approves Opening of Fourth Group in Phase 1 Trial to Treat Metastatic Cancers - Marketscreener.com
TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial - Longview News-Journal
Transcode Therapeutics Inc Stock (RNAZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):